TaiGen Biotechnology Co., Ltd. announced today that in a phase 1 study in healthy volunteers TG-0054, a chemokine receptor CXCR4 antagonist, was well tolerated and rapidly mobilized stem cells and endothelial progenitor cells from bone marrow into peripheral blood. The number of CD34+ stem cells in circulation after one dose of TG-0054 was equal or higher than reported cell numbers needed for stem cell transplantation in cancer patients. The observed AEs were all mild and transient. A phase 2 study in stem cell transplantation for multiple myeloma, non-Hodgkin lymphoma and Hodgkin disease patients is currently being initiated (…)
“We are greatly encouraged by the phase 1 study results which indicates that TG-0054 has the potential to be used alone, not in combination with G- CSF, for allogenic or autologous stem cell transplantation in cancer patients. This should greatly reduce the hospital and other associated cost for such a procedure. Importantly, the activity and safety profile in the phase 1 study will support our future development of TG-0054 in chemosensitization and tissue ischemia, including myocardial infarction, stroke and severe intermittent claudication. Our preclinical animal disease models and the phase 1 study results lend strong support to clinical development for these clinical indications,” said Dr. Ming-Chu Hsu, Chairman & CEO of TaiGen (…)
BRITISH face surgeons are to grow new skull, cheek and jaw bones on patients’ backs using their own stem cells.
The surgeons, from Barts and the London NHS Trust, hope to use the technique to help people whose facial bones have been destroyed by cancer or injury.
Four patients are awaiting the treatment, which the surgeons believe could eventually become a less risky alternative to face transplants. Two are cancer victims and two have had accidents.
The team, led by Iain Hutchison, will make the first attempt to grow replacement bone from a patient’s own stem cells in Britain.
The procedure involves constructing a mould in the shape of the bone required and filling it with the patient’s bone marrow. This contains stem cells which can be persuaded to grow into different types of tissue. A genetically modified protein coaxes the stem cells to grow into bone. The mould is then inserted into the patient’s back muscles below the shoulder blade where it establishes a blood supply from the patient.
It is left to grow there for three to six months when it will be transplanted onto the patient’s face.
According to Hutchison, the stem cell procedure also has advantages over existing techniques of removing bones from other parts of the body. (…)
Read full article on Times Online
Hong Kong scientists say they have identified the cancer stem cells responsible for the spread of colorectal cancer to other organs and believe the find will revolutionise treatment.
Current treatments regard all cancer cells as alike, but the Hong Kong University researchers discovered that cancers contain a small number of stem cells responsible for starting and maintaining tumours.
“It will revolutionise the approach to cancer treatment in future,” one researcher, Ronnie Poon, told the South China Morning Post.
Plerixafor has allowed doctors to collect stem cells from patients where there had been previous difficulties.
The drug, which has only recently been licensed, is being used at the Beatson West of Scotland Cancer Centre.
Stem cells therapies are used to treat people with cancer of the blood. The cells are collected and reintroduced to a patient after chemotherapy.
Doctors often encounter problems collecting enough stem cells from about one in 10 cancer patients to undergo treatment.
Plerixafor has, so far, had a 100% success rate in allowing doctors at the cancer centre to collect enough cells from patients who fall into this category.
Blood specialist, Dr Kenneth Douglas, explained how the drug worked.
“Basically it blocks a chemical scent that stem cells sniff for that tells them they’re in the bone marrow,” he said.
“If you block that chemical scent they get confused and agitated and they think they are not in the bone marrow any more and they start wandering into the blood stream looking for the bone marrow.”
When more stem cells “start wandering into the blood” doctors are able to collect them for future treatment.
One patient who has benefited from this approach is retired professional golfer, Billy McCondachie.
He said his age was a barrier to potential stem cell treatment.
“We were only able to get about half of my stem cells out until Dr Douglas came along with this new drug,” he said.
“One could say that pretty much saved my life.”
The centre in Glasgow has now treated 13 people with the drug and every one has been able to proceed with stem cell treatment.
from BBC news
The team at Children’s Hospital Boston and the Harvard Stem Cell Institute were working with a new type of cell called induced pluripotent stem cells or iPS cells, which closely resemble embryonic stem cells but are made from ordinary skin cells.
In this case, they wanted to study a rare, inherited premature aging disorder called dyskeratosis congenita. The blood marrow disorder resembles the better-known aging disease progeria and causes premature graying, warped fingernails and other symptoms as well as a high risk of cancer.
One of the benefits of stem cells and iPS cells is that researchers can make them from a person with a disease and study that disease in the lab. Harvard’s Dr. George Daley and colleagues were making iPS cells from dyskeratosis congenita patients to do this (…)